CA
NZ
UK
AU
IND
US
Kura Oncology (NASDAQ: KURA) is a biotechnology firm with a market capitalisation of $874 million, $67.48 million of trailing‑twelve‑month revenue and $70.24 million of cash and equivalents. It employs 260 people and carries $9.79 million of reported debt, giving it a debt‑to‑equity ratio of …
Mannatech, Incorporated (NASDAQ: MTEX) reported a significant uptick in net sales for the second quarter of 2026, reaching $26.7 million, a $1.0 million increase from the prior year's figures. As the health and wellness firm navigates a challenging market environment, the uptick in sales …
22nd Century Group, Inc. (NASDAQ: XXII) has posted second quarter 2026 net revenues of $2.9 million, a significant decrease from $4.1 million recorded in the first quarter. This decline reflects the company's ongoing struggles toCapitalizeon its VLN® product offerings, despite an expanded retail presence. …
The reported earnings per share of negative $0.13 comfortably outperformed the consensus expectation of negative $0.17, indicating that the company managed to limit its losses better than analysts had projected. This modest earnings beat, while still reflecting a loss, can be interpreted by investors …
Those figures highlight the impact of a rapidly expanding store network and a shift toward higher‑margin branded sales.
BioCardia Inc. (NASDAQ: BCDA), a biotechnology firm focused on cellular therapies for cardiovascular diseases, reported its second quarter 2026 earnings, showing an earnings per share (EPS) of $-0.13. This figure was better than analyst expectations, which averaged $-0.18. However, the company continues to struggle …
The New York Academy of Medicine (NYAM) is set to host its annual gala on October 28, 2026, highlighting four influential leaders in the healthcare sector. The event recognizes contributions from diverse fields, including clinical care, health communication, and system transformation. This year's honorees …
Eli Lilly and Company (NYSE: LLY), a leading player in the pharmaceutical industry with a marketCapitalizationof $1.12 trillion, reported a remarkable 48% increase in second-quarter revenue, bringing it to $23 billion. This growth, primarily driven by strong sales of Mounjaro and Zepbound, far surpasses …
Hims is gearing up to launch its peptide products, but investor apprehension is overshadowing this key moment. Shares of the company have declined asWall Streetanalysts express skepticism regarding Hims' prospects in the competitive peptide market. Peptides are emerging as a popular choice in healthcare, …
Earth Science Tech, Inc. (OTC: ETST) operates as a diversifiedHolding Companyconcentrated on health‑and‑wellness solutions, positioning itself across multiple sub‑segments of the industry. The market recognises the firm with aMarket Capitalisationof $28.47 million, while its trailing‑twelve‑month revenue reached $35.96 million, reflecting an 8.0% year‑over‑year increase. …
Please wait processing your request...